Ph II/III trial of Somaxon's nalmefene still recruiting
The USA's Somaxon Pharmaceuticals says that the February issue of the American Journal of Psychiatry features an article which describes the conduct and results of a four-month clinical trial investigating the efficacy and safety of its drug candidate oral nalmefene hydrochloride, an opioid antagonist, in reducing pathological gambling-related urges, thoughts and behaviors.
Finnish drugmaker BioTie Therapies sponsored the trial, which was completed in April 2003 and, in November 2004, Somaxon exclusively licensed certain patents from the firm to develop, manufacture and market nalmefene in North America. The US company is currently enrolling patients in an ongoing, multicenter Phase II/III clinical trial investigating the use of the agent in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze